Study #2016-0596
A Phase I/II, Multicenter, Open-Label Study Of MAK683 In Adult Patients With Advanced Malignancies
MD Anderson Study Status
Not Accepting
Treatment Agent
MAK683
Description
The purpose of this Phase I/II study is to establish the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) and to evaluate the safety, antitumor activity and pharmacokinetic (PK) profile of MAK683 in patients with advanced malignancies such as Diffuse Large B cell Lymphoma (DLBCL), nasopharyngeal carcinoma (NPC) or other advanced solid tumors for whom no further effective standard treatment is available.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Diffuse Large B-cell Lymphoma
Study phase:
Phase I
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-537-9578
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.